Isoniazid

CHEMBL64 Phase 4 معتمد Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
137.1 g/mol
LogP
-0.7
Phase
4

This first-line antibiotic is used to treat and prevent tuberculosis (TB) by inhibiting mycolic acid synthesis, a key component of the mycobacterial cell wall. It is one of the most important TB drugs and is used in combination with other agents to prevent the development of resistance. Long-term use requires supplementation with vitamin B6 (pyridoxine) to prevent peripheral neuropathy.

الوزن الجزيئي

137,1400 g/mol

LogP

-0,70

TPSA

68,00 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

آلية العمل

Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

NNC(=O)c1ccncc1

InChI

InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)

Molecular Formula

C6H7N3O

HBD / HBA

2 / 3

الروابط القابلة للدوران

1

الذرات الثقيلة

10

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

This first-line antibiotic is used to treat and prevent tuberculosis (TB) by inhibiting mycolic acid synthesis, a key component of the mycobacterial cell wall. It is one of the most important TB drugs and is used in combination with other agents to prevent the development of resistance. Long-term use requires supplementation with vitamin B6 (pyridoxine) to prevent peripheral neuropathy.

Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.

Yes, Isoniazid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL64. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3767. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.